Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.9% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
0
users have commented on this narrative
36
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Peach Property Group
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Stefanie Koch And Refinancing Will Improve Operational Efficiency
Key Takeaways Operational efficiency gains and strategic focus on reducing vacancy rates are anticipated to boost net margins and earnings. Financial restructuring through asset sales and debt reduction strengthens financial position and supports potential revenue growth.
View narrative
CHF 7.77
FV
12.5% undervalued
intrinsic discount
-7.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
7 days ago
author updated this narrative
Codexis
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
ECO Synthesis Launch In 2025 Will Unlock Pharma Contracts
Key Takeaways Transitioning to commercial execution with ECO Synthesis and partnerships enhances revenue growth by securing new contracts and expanding into pharma and biotech segments. GMP production and collaborations with siRNA drug innovators drive long-term profitability, supporting future large-scale manufacturing and revenue sustainability.
View narrative
US$7.08
FV
56.2% undervalued
intrinsic discount
33.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
7 days ago
author updated this narrative
ClearPoint Neuro
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Cell And Gene Therapy Delivery Will Expand Global Partnerships
Key Takeaways Strategic partnerships and global expansion aim to boost revenue and earnings through enhanced technology access and new pharma agreements. Efficiency-focused hospital products and increased trial capabilities target significant market growth and improved net margins.
View narrative
US$29.00
FV
59.7% undervalued
intrinsic discount
24.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
7 days ago
author updated this narrative
3D Systems
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Regenerative Medicine And Dental Focus Will Open New Markets
Key Takeaways Collaborations in regenerative medicine and dental market focus position 3D Systems for potential future revenue growth. Cost reduction initiatives aim to boost profitability through improved gross margins and EBITDA.
View narrative
US$3.00
FV
30.3% undervalued
intrinsic discount
-4.61%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
20
users have followed this narrative
7 days ago
author updated this narrative
kneat.com
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Digital Validation Will Unlock Expansion In Regulated Industries
Key Takeaways Strong demand for digital validation in regulated industries, coupled with product enhancements, drives recurring revenue growth and expands margin potential amid rising regulatory complexity. Land-and-expand strategy, flexible platform, and broader vertical reach deepen customer relationships, support price resilience, and fuel robust, visible future growth.
View narrative
CA$7.95
FV
28.4% undervalued
intrinsic discount
29.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
7 days ago
author updated this narrative
CVRx
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
CPT Code Change Will Expand Heart Failure Treatment Adoption
Key Takeaways Upcoming reimbursement improvements and expanded clinical evidence are set to boost physician adoption, leading to higher procedure volumes and increased revenue leverage. Strategic sales force expansion and targeted education will drive sustained demand, better market penetration, and enhanced long-term profitability.
View narrative
US$10.83
FV
33.2% undervalued
intrinsic discount
21.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
7 days ago
author updated this narrative
Alpha Teknova
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Acquisitions And Collaborations Will Expand Cell And Gene Therapy Portfolio
Key Takeaways Expansion through collaborations and acquisitions aims to boost top-line growth, margins, and financial stability amidst anticipated market rebound. Focus on supporting Cell and Gene Therapy promises substantial revenue gains from clinical phase progressions, while custom product growth targets strengthen revenue prospects.
View narrative
US$10.00
FV
51.2% undervalued
intrinsic discount
14.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
7 days ago
author updated this narrative
Spire Global
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Advanced Weather Models And Space Reconnaissance Will Define Our Future
Key Takeaways Strategic positioning in space-based weather data and shifts in government contracts can drive substantial revenue growth opportunities. Leveraging advanced AI models, operational improvements, and a new space reconnaissance unit enhances Spire's market responsiveness and revenue potential.
View narrative
US$15.60
FV
34.1% undervalued
intrinsic discount
0.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
7 days ago
author updated this narrative
Quanterix
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Simoa ONE Platform Will Revitalize Immunology And Oncology Markets
Key Takeaways Strategic product expansion and key acquisitions could significantly enhance market reach and revenue potential in immunology and oncology markets. Focus on diagnostics and recurring revenue streams is likely to improve profitability and operational efficiency, paving the way to positive cash flow.
View narrative
US$11.00
FV
58.7% undervalued
intrinsic discount
10.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
7 days ago
author updated this narrative
Value any company in seconds
Popular companies